JPS62142567A - Double filtering type blood treatment apparatus - Google Patents
Double filtering type blood treatment apparatusInfo
- Publication number
- JPS62142567A JPS62142567A JP60284797A JP28479785A JPS62142567A JP S62142567 A JPS62142567 A JP S62142567A JP 60284797 A JP60284797 A JP 60284797A JP 28479785 A JP28479785 A JP 28479785A JP S62142567 A JPS62142567 A JP S62142567A
- Authority
- JP
- Japan
- Prior art keywords
- plasma
- blood
- pump
- valve
- separator
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004369 blood Anatomy 0.000 title claims description 94
- 239000008280 blood Substances 0.000 title claims description 94
- 238000001914 filtration Methods 0.000 title claims description 8
- 239000012530 fluid Substances 0.000 claims description 33
- 230000017531 blood circulation Effects 0.000 claims description 27
- 210000000601 blood cell Anatomy 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 7
- 239000000706 filtrate Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 description 21
- 238000000926 separation method Methods 0.000 description 12
- 238000000034 method Methods 0.000 description 11
- 239000007788 liquid Substances 0.000 description 9
- 230000007423 decrease Effects 0.000 description 6
- 238000010586 diagram Methods 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000004872 arterial blood pressure Effects 0.000 description 3
- 239000012510 hollow fiber Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 229920000219 Ethylene vinyl alcohol Polymers 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 239000004715 ethylene vinyl alcohol Substances 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- RZXDTJIXPSCHCI-UHFFFAOYSA-N hexa-1,5-diene-2,5-diol Chemical compound OC(=C)CCC(O)=C RZXDTJIXPSCHCI-UHFFFAOYSA-N 0.000 description 2
- 230000036470 plasma concentration Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 101000650578 Salmonella phage P22 Regulatory protein C3 Proteins 0.000 description 1
- 241000207961 Sesamum Species 0.000 description 1
- 235000003434 Sesamum indicum Nutrition 0.000 description 1
- 101001040920 Triticum aestivum Alpha-amylase inhibitor 0.28 Proteins 0.000 description 1
- BZHJMEDXRYGGRV-UHFFFAOYSA-N Vinyl chloride Chemical compound ClC=C BZHJMEDXRYGGRV-UHFFFAOYSA-N 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000001112 coagulating effect Effects 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002637 fluid replacement therapy Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
Landscapes
- External Artificial Organs (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。(57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】
ＣＩＩＩ！上の利用分野〕
この発明は血液から、血球成分と血漿成分を分離する血
漿分離器と１分離した血漿から高分子量成分を除去する
血漿成分分離器とを有する二重濾過型血液処理装置、特
に流路等に残留する血液等を自動的に患８１と戻す装置
に関するものである。[Detailed Description of the Invention] CIII! [Field of Application] This invention relates to a double filtration type blood processing device having a plasma separator that separates blood cell components and plasma components from blood, and a plasma component separator that removes high molecular weight components from the separated plasma. This invention relates to a device that automatically returns blood, etc. remaining in a flow path etc. to a patient 81.
腎不全、肝不全、自己免疫疾患等の治療法として、患者
の血液を血漿分離器で血漿成分と血球成分とに分離し１
分離した血漿成分を、血漿成分分離器で有害物質が含ま
れる毘分子量成分と、アルブミン等の人体に有害な物質
が含まれる低分子量成分とに分離し、低分子量成分に高
分子量成分と等量の補液を加えて体内に返還する二重濾
過［［［ｌｆ１分離交換法が知られている（特公昭６０
−４０３０２号公報など）。この揮の血液処理方法では
、血液を処理した後に、血漿分離器、血漿成分分離器お
よび流路中に残存する血液や血漿などを患者に戻す、い
わゆる回収処理を施す必要がある。As a treatment for kidney failure, liver failure, autoimmune diseases, etc., the patient's blood is separated into plasma components and blood cell components using a plasma separator.
The separated plasma components are separated by a plasma component separator into high molecular weight components that contain harmful substances and low molecular weight components that contain substances harmful to the human body such as albumin, and the low molecular weight components are divided into equal amounts of high molecular weight components. The double filtration [[[lf1 separation and exchange method] is known (Special Publication Act, 1983), in which a replacement fluid is added and returned to the body.
-40302, etc.). In this conventional blood processing method, after blood is processed, it is necessary to perform a so-called recovery process in which the blood, plasma, etc. remaining in the plasma separator, plasma component separator, and flow path are returned to the patient.
従来の回収処理は、上記したように分離器が２つ設けら
れていて、装置全体が複雑であるため、各ポンプの駆動
と停止）１．を繰り返したり、各ポンプの流量を調節し
たり、あるいはペアン等を使用して流路を開閉する操作
は主に手作業で行なわれていた。In the conventional recovery process, as mentioned above, two separators are provided, and the entire device is complicated, so each pump needs to be driven and stopped.1. Operations such as repeating the steps, adjusting the flow rate of each pump, or opening and closing the flow channels using a Pean or the like were mainly performed manually.
上述の回収処理は装置が複雑なため面倒で、時間がかか
り、操作が煩雑で操作員の習熟したテクニックを必要と
した。The above-mentioned collection process is troublesome and time-consuming due to the complicated equipment, and the operation is complicated and requires a skilled operator.
本発明は従来の上記問題を解消して、血漿分離器−血漿
成分分離器、流路中に残った血液や血漿等を効率よく、
患者の体内に自動的に回収する二重濾過型血液処理装置
を提供することを目的とする。The present invention solves the above-mentioned conventional problems and efficiently removes blood, plasma, etc. remaining in the plasma separator-plasma component separator and flow path.
It is an object of the present invention to provide a double filtration type blood processing device that automatically collects blood into a patient's body.
上記目的を達成するための、この発明の構成をＩ！１図
に示す。The structure of this invention to achieve the above object is I! Shown in Figure 1.
血液循環流路１には、血液導出部Ｈｔから取り出された
血液を血球成分と血漿成分とに分離する血漿分離器３と
、血液ポンプ４とが接続され、分離され良血球成分は静
脈圧チャンバー１８を経由して、血液導入部■２より、
人体に戻す。血漿分離器３の血球成分の出口側には流路
を外部からピンチして開閉する第２のバルブ１７があり
、第２のバルブの下流側には気液を分離するための静脈
チャンバーｌＳが接続されている。該静脈チャンバー１
８の下流には流路中の空気の存在を見料ける第２の検出
器１９があり、その検出器１９と血液導入部山間には、
流路を外部からピンチして開閉する第１のバルブ２０が
設けられている。静脈チャンバー１８にはチャンバー内
の液体レベルが適正レベル（チャンバーの下限より約２
／３の位置）まで存在するか否かを識別する第１の検出
器１８Ｄが備えである。A blood pump 4 and a plasma separator 3 that separates the blood taken out from the blood outlet Ht into blood cell components and plasma components are connected to the blood circulation channel 1, and the separated good blood cell components are transferred to a venous pressure chamber. From blood introduction part ■2 via 18,
Return to human body. On the outlet side of the blood cell component of the plasma separator 3, there is a second valve 17 that opens and closes the flow path by pinching from the outside, and on the downstream side of the second valve, there is a venous chamber IS for separating gas and liquid. It is connected. The venous chamber 1
8, there is a second detector 19 that can detect the presence of air in the flow path, and between the detector 19 and the blood introduction part mountain,
A first valve 20 is provided that opens and closes the flow path by pinching it from the outside. The venous chamber 18 has a liquid level within the chamber at an appropriate level (approximately 2 below the lower limit of the chamber).
/3 position) is provided.
血漿流路２には、上記血漿分離器３で分離された血漿成
分を高分子量成分と低分子量成分に分離する血漿成分分
離器６、血漿ポンプ７１および補液ポンプ７２と血漿流
路２の流量を検知する検知器８が接続され１分離された
低分子量成分を、上記血漿分離器３の下流の血液循環流
路１を口を経て人体へ戻す。一方分離された高分子量成
分はドレン開口りから外部へ排出される。また補液は補
液供給限０から高分子量成分と等量の補液を血漿成分分
離器６に供給し、低分子量成分と混合して人体へ送給さ
れる。The plasma flow path 2 includes a plasma component separator 6 that separates the plasma components separated by the plasma separator 3 into high molecular weight components and low molecular weight components, a plasma pump 71, a fluid replacement pump 72, and a flow rate of the plasma flow path 2. A detector 8 is connected and the separated low molecular weight components are returned to the human body through the blood circulation channel 1 downstream of the plasma separator 3 through the mouth. On the other hand, the separated high molecular weight components are discharged to the outside through the drain opening. Further, the replacement fluid is supplied from the replacement fluid supply limit 0 to the plasma component separator 6 in an amount equal to the high molecular weight component, mixed with the low molecular weight component, and then delivered to the human body.
血漿流路２の血漿ポンプ７１と、血漿成分分離器６０間
には液体と気体を分離する２次膜チャンバー３２が備え
られている。このチャンバー３２には、圧力を検知する
第３の検出器３７が接続され、また該チャンバー３２に
は液体レベルが適正レベルまで存在するか否かを識別す
る第４の検出器３９が備えらｎている。A secondary membrane chamber 32 for separating liquid and gas is provided between the plasma pump 71 of the plasma flow path 2 and the plasma component separator 60. A third detector 37 for detecting pressure is connected to this chamber 32, and the chamber 32 is equipped with a fourth detector 39 for determining whether the liquid level is at a proper level. ing.
血漿流路２の下流側と血液循環流路】との間には、２つ
の流路の連通と遮断を行う第３のバルブ１１が設けられ
ている。A third valve 11 is provided between the downstream side of the plasma flow path 2 and the blood circulation flow path for communicating and blocking the two flow paths.
血漿分離器３の炉液（血漿）室の上部側壁に設けた開口
には第４のバルブ２５が接続されており、この第４のバ
ルブ２５により、外部空気を炉液室内に導入できる。外
部空気による汚染をさけるため、第４のバルブ２５の空
気取入口には除菌フィルターを設ける事が好ましい。A fourth valve 25 is connected to an opening provided in the upper side wall of the furnace liquid (plasma) chamber of the plasma separator 3, and this fourth valve 25 allows external air to be introduced into the furnace liquid chamber. In order to avoid contamination by external air, it is preferable to provide a sterilization filter at the air intake port of the fourth valve 25.
一方、制御手段としては、血液回収手段１３、血漿回収
手段１５、補液回収手段１４および回収終了手段１６が
ある。On the other hand, the control means includes blood collection means 13, plasma collection means 15, replacement fluid collection means 14, and collection termination means 16.
血液処理が終了すると、血液導出部Ｈｓを人体から取り
外し、その後外部からのスタート信号を受ける。血液回
収手段１３は第１のバルブ２０および第２のバルブ１７
の開信号、第３のバルブ１１の閉信号を送り、血液ポン
プ４を駆動させて、血液循環流路中に残った血液を血液
ポンプ４により血漿分離器３．静脈チャンバー１８を経
由して血液導入部Ｈ２より人体に返却１−る。その際人
体から取り外された血液導出部Ｕｌからは空気が入る。When the blood treatment is completed, the blood lead-out section Hs is removed from the human body, and then a start signal is received from the outside. The blood collection means 13 includes a first valve 20 and a second valve 17.
An open signal to the third valve 11 and a close signal to the third valve 11 are sent to drive the blood pump 4, and the blood remaining in the blood circulation channel is transferred to the plasma separator 3. The blood is returned to the human body from the blood introduction section H2 via the venous chamber 18. At this time, air enters from the blood lead-out portion Ul removed from the human body.
そして血漿分離器３の残血液が無くなると静脈チャンバ
ー１８の血液レベルが低下し、第１の検出器１８Ｄで気
体（空気）がある一定期間検出される。When the remaining blood in the plasma separator 3 disappears, the blood level in the venous chamber 18 decreases, and gas (air) is detected for a certain period of time by the first detector 18D.
すると血液の回収が終了したものとみなし、血漿回収手
段１５により第２のバルブ１７の閉信号、第３のバルブ
１１および第４のバルブ２５の開信号を送り血液ポンプ
４の駆動を停止させ、血漿ポンプ７１を駆動する。する
と外部空気が第４のバルブ２５からとり込まれ、血漿分
離器３内の残血漿は２成膜チャンバー３２を経由して、
血漿成分分離器６に送り込まれる。この残血漿は血漿成
分分離器内の分離膜を通過して第３のバルブ１１を通り
一血液循環流路１の静脈チャンバー１８を経由して、血
液導入部■２から体内に戻される。血漿分離器３から残
血漿が送り出されてしばらくすると、２成膜チャンバー
３２に第４のバルブ２５からとり込まれた空気が送り込
まれ、チャンバー内の液体（血漿）レベルが低下して２
成膜チャンバー３２に設けられた第４の検出器３９が気
体（空気）を検出すると同時に流量計８により累積流量
を算出し、そのＸ積流量が所定値（血漿成分分離器６の
“分離膜容積に相当する量）に到達すると、補液回収手
段１４により補液ポンプ７２を駆動して、補液流路内の
残補液及び血漿成分分離器６内の残血漿を人体に戻す。Then, it is assumed that the blood collection has been completed, and the plasma collection means 15 sends a close signal to the second valve 17 and an open signal to the third valve 11 and the fourth valve 25, and the drive of the blood pump 4 is stopped. The plasma pump 71 is driven. Then, external air is taken in from the fourth valve 25, and the remaining plasma in the plasma separator 3 passes through the second film forming chamber 32.
It is sent to a plasma component separator 6. This remaining plasma passes through the separation membrane in the plasma component separator, passes through the third valve 11, passes through the venous chamber 18 of the blood circulation flow path 1, and is returned to the body from the blood introduction part 2. After a while after the remaining plasma is sent out from the plasma separator 3, the air taken in from the fourth valve 25 is sent into the second film forming chamber 32, and the liquid (plasma) level in the chamber decreases.
The fourth detector 39 installed in the film forming chamber 32 detects gas (air), and at the same time the flow meter 8 calculates the cumulative flow rate, and the When the amount corresponding to the volume is reached, the replacement fluid collecting means 14 drives the replacement fluid pump 72 to return the remaining replacement fluid in the replacement fluid channel and the remaining plasma in the plasma component separator 6 to the human body.
この時、２成膜チャンバー３２に接続されて該チャンバ
ー内の圧力を検出する＃Ｉ３の検出器３７が所望の圧力
になる様、血漿ポンプ７１は起動停止（又は連続的な回
転上昇下降）する。その際少くとも血漿成分分離器の分
離膜内に血漿が逆流しない様に考慮する必要がある。At this time, the plasma pump 71 starts and stops (or continuously rotates up and down) so that the #I3 detector 37 connected to the second film forming chamber 32 and detects the pressure inside the chamber reaches the desired pressure. . At this time, it is necessary to take into account at least the possibility that plasma will not flow back into the separation membrane of the plasma component separator.
補液容器９内の補液がなくなると、補液容器に取着され
た空気導入口（通常容器に注射針を穿刺する）より空気
が吸い込まれ、この空気は血漿成分分離器６、第３のバ
ルブ１１を通り血液循環流路ｌの静脈チャンバー１８か
ら第２の検出器１９へ至る。該第２の検知器１９が上記
空気（気体）を検出すると、この信号を受けて回収終了
手段１５により血漿ポンプ７１と補液ポンプ７２の駆動
を停止し、かつ第１のバルブ２０を閉止する。When the replacement fluid in the replacement fluid container 9 runs out, air is sucked in through the air inlet (usually a needle is inserted into the container) attached to the replacement fluid container, and this air is passed through the plasma component separator 6 and the third valve 11. from the venous chamber 18 of the blood circulation channel 1 to the second detector 19. When the second detector 19 detects the air (gas), in response to this signal, the collection termination means 15 stops driving the plasma pump 71 and the replacement fluid pump 72, and closes the first valve 20.
上記により回収が終了するか゛、このとき血液循環流路
１の第２の検出器１９から血液導入部１１２の間には血
漿が残留している。この残留血漿をも回収する場合には
例えばスタートスイッチ信号により、第１のバルブ２０
の開信号を送り一補液ポンプ７２を起動し、残血漿を血
液導入部Ｈ２に目視にて近接させる。その後ストップス
イッチ信号により補液ポンプ７２を停止し、第１のバル
ブ２ｏの閉信号を送る。上記操作は通常手動で行われる
。Although the collection is completed as described above, at this time, plasma remains between the second detector 19 and the blood introduction part 112 of the blood circulation channel 1. If this residual plasma is also to be collected, the first valve 20 is activated by a start switch signal, for example.
An open signal is sent to start the replacement fluid pump 72, and the remaining plasma is visually brought close to the blood introduction part H2. Thereafter, the replacement fluid pump 72 is stopped by a stop switch signal, and a signal to close the first valve 2o is sent. The above operations are usually performed manually.
血液の回収に生理食塩水を使用する場合には血液導出部
Ｈ１を生食ボトルに接続すればよい。その場合にも静脈
チャンバー１８に設けられたＩｊｌｌの検出器１８Ｄが
気体（空気）を検出したときを回収終了とみなすことが
できる。生理食塩水で血液を回収すると第１の検出器１
８Ｄは血液、次に生理食塩水を検出し、その次に気体（
空気）を検出するため、血液の回収番ζ多少長時間を要
することになるだけで、上記の空気による血液の体内返
却と同一の工程で実施出来る。When using physiological saline to collect blood, the blood outlet H1 may be connected to a saline bottle. In that case as well, when the Ijll detector 18D provided in the venous chamber 18 detects gas (air), it can be considered that the collection is complete. When blood is collected with physiological saline, the first detector 1
8D detects blood, then saline, then gas (
This method can be carried out in the same process as the above-mentioned method for returning blood into the body using air, except that the blood collection step ζ requires a slightly longer time to detect air (air).
上記構成によれば、血液処理終了後、血液導出部Ｈ１を
人体より取り外し、しかる後□回収処理をスタートさせ
ることにより、直ちに体外に導出された残血液を大部分
、体内に返却出来る。According to the above configuration, most of the remaining blood drawn out of the body can be immediately returned to the body by removing the blood lead-out section H1 from the human body after the blood treatment and then starting the recovery process.
また、残血漿のすべては血漿成分分離器６へ送られ、低
分子量成分のみ分離膜を通過［、て人体に返却される。Further, all of the remaining plasma is sent to a plasma component separator 6, where only low molecular weight components pass through a separation membrane and are returned to the human body.
しかも残血液も全て人体に返却されるため効率的な回収
が出来る。Furthermore, all remaining blood is returned to the human body, allowing for efficient recovery.
また血液回収手段、血漿回収手段、補液回収手段および
回収終了手段が継続して自動的に作動する為、操作が極
めて簡単になり、スタート操作のみで残血液、残血漿の
ほとんどすべてが回収される。In addition, since the blood collection means, plasma collection means, replacement fluid collection means, and collection termination means operate continuously and automatically, the operation is extremely simple, and almost all of the remaining blood and plasma can be collected with just the start operation. .
以下、この発明の実施例を図面にしたがって説明する。 Embodiments of the present invention will be described below with reference to the drawings.
まず、二重濾過型血液処理装置について説明する。First, a double filtration type blood processing device will be explained.
ｆＰＺ図は血液処理時のフロー図であり、１は血液循環
流路、２は血漿流路である。血液導入部Ｂｉｔ（シャン
ト、注射針などの通常の採血器や貯血器などと連絡でき
る部分）から取り出された血液は、血液ポンプ４により
昇圧されて動脈圧チャンバー１６に入り、ついで、上下
方向に設定された血漿分離器３に上側から導入され、血
球成分と血漿成分とに分離される。この血漿分離器３に
は、１Ｔｌｔ漿分離膜、たとえばポリビニルアルコール
（１’ＶＡ）系の共重合体などからなる平板状、チュー
ブ状、または中空糸状の分離膜が収容されている。通常
は、中空糸状の分離膜を多数寄せ集め九ものが用いられ
る。The fPZ diagram is a flow diagram during blood processing, where 1 is a blood circulation flow path and 2 is a plasma flow path. Blood taken out from the blood introduction part Bit (a part that can communicate with a normal blood collection device such as a shunt or a syringe needle or a blood storage device) is pressurized by the blood pump 4 and enters the arterial pressure chamber 16, and then flows upward and downward. The blood is introduced from above into the set plasma separator 3 and separated into blood cell components and plasma components. The plasma separator 3 accommodates a 1Tlt plasma separation membrane, such as a plate-shaped, tube-shaped, or hollow fiber-shaped separation membrane made of a polyvinyl alcohol (1'VA) copolymer. Usually, nine hollow fiber separation membranes are used.
上記血漿分離器３で分離され九血球成分は、第２のパル
プ１７を経て静脈圧チャンバー１８に入り気泡検知器１
９、第１のパルプ２０を経て血液導出部Ｈ２（シャント
や点滴セットなどに連結できる部分）へ戻る。静脈圧チ
ャンバーには、チャンバー−レベルをモニターする検知
器ＩＢＤが設けられている。The nine blood cell components separated by the plasma separator 3 pass through the second pulp 17 and enter the venous pressure chamber 18 into the bubble detector 1.
9. Return to the blood outlet H2 (portion that can be connected to a shunt, drip set, etc.) via the first pulp 20. The venous pressure chamber is equipped with a detector IBD that monitors the chamber level.
さらに、上記血液ポンプ４の上流側には、膨張・収縮可
能な袋状体からなるビローセンサ２１が設けられており
、脱血が困難になったときに、流路の陽圧を検知して作
動し、血液ポンプ４を停止させ、陽圧がなくなったとき
、血液ポンプ４を再始動する。また、上記動脈圧チャン
バー１６には、血液中にヘパリンを少量だけ混入させて
、処理中の血液の凝固を防止するヘパリン注入器２２と
。Furthermore, a billow sensor 21 made of a bag-like body that can be expanded and contracted is provided upstream of the blood pump 4, and is activated by detecting positive pressure in the flow path when blood removal becomes difficult. Then, the blood pump 4 is stopped, and when the positive pressure disappears, the blood pump 4 is restarted. The arterial pressure chamber 16 also includes a heparin injector 22 that mixes a small amount of heparin into the blood to prevent blood from coagulating during treatment.
動脈圧センサ１２３とが接続され、上記血漿分離器３に
は、濾過圧センサ２４と空気導入パルプ２５とが接続さ
れ、上記静脈圧チャンバー１８には、静脈圧センサ２６
が接続されている。An arterial pressure sensor 123 is connected, a filtration pressure sensor 24 and an air introduction pulp 25 are connected to the plasma separator 3, and a venous pressure sensor 26 is connected to the venous pressure chamber 18.
is connected.
上記血漿分離器３で分離された血漿成分は、血漿流路２
の血漿ポンプ７１により昇圧されて２次膜圧チャンバー
３２に入り、上下方向に設定された血漿成分分離器６に
下側から導入されて一高分子量成分と低分子量成分とに
分離される。この血漿成分分離器６には、血漿処理膜、
たとえばエチレンビニルアルフール（ＥＶム）系の共重
合体などから′なる平゛稜状、チューブ状、または中空
糸状の分離膜が収容されている。通常は、中空糸状の分
離膜を多数寄せ集めたものが用いられる。The plasma components separated by the plasma separator 3 are transferred to the plasma flow path 2
The plasma is pressurized by the plasma pump 71, enters the secondary membrane pressure chamber 32, is introduced from below into the plasma component separator 6 set vertically, and is separated into a high molecular weight component and a low molecular weight component. This plasma component separator 6 includes a plasma processing membrane,
A flat, tubular, or hollow fiber separation membrane made of, for example, an ethylene vinyl alcohol (EV) copolymer is accommodated therein. Usually, a collection of a large number of hollow fiber separation membranes is used.
上記血漿成分分離器６で分離された高分子量成分は、ド
レンポンプ７２により、血漿成分分離器６の上方からド
レン開口りを経て外部へ排出される。−万、低分子量成
分は、血漿分離器３よりも下流の血液循環流路１を経て
人体へ戻される。The high molecular weight components separated by the plasma component separator 6 are discharged from above the plasma component separator 6 to the outside through a drain opening by a drain pump 72. - 10,000, the low molecular weight components are returned to the human body via the blood circulation channel 1 downstream of the plasma separator 3.
上記２次膜圧チャンバー３２には、２次膜圧センサ３７
、空気放出バルブ３８および液面検知センサ３９が接続
され、上記血漿成分分離器６には、上記ドレンポンプ７
２および気泡検知器４０を介して、補液導入部（点滴セ
ットなどに連結できる部分）が、アルブミンやＨＦ２等
の補液を供給する補液供給源９に接続され、補液が上記
ドレンボら
ンプ７２により血漿成分分離器６内へ送よれて、低分子
量成分に混入される。The secondary membrane pressure chamber 32 includes a secondary membrane pressure sensor 37.
, an air release valve 38 and a liquid level detection sensor 39 are connected to the plasma component separator 6, and the drain pump 7 is connected to the plasma component separator 6.
2 and the air bubble detector 40, the replacement fluid introduction part (a part that can be connected to an intravenous drip set, etc.) is connected to a replacement fluid supply source 9 that supplies replacement fluid such as albumin or HF2, and the replacement fluid is supplied to plasma via the drain lamp 72. It is sent into the component separator 6 and mixed with low molecular weight components.
また、血漿分離器３の下流側に、第２のパルプ１７が設
けられ、上記血漿流路２の下流側と血液循環流路１の第
２のパルプ１７よりも下流側との間には、連通およびし
ゃ断を行なう第３のパルプ１１が設けられている。Further, a second pulp 17 is provided downstream of the plasma separator 3, and between the downstream side of the plasma flow path 2 and the downstream side of the second pulp 17 of the blood circulation flow path 1, A third pulp 11 is provided for communication and interruption.
ざらに上記血液ポンプ４には、この血液ポンプ４の回転
数に基づいて血液循環流路１の流量を検知する血液量検
知器５が、上記血漿ポンプ７１には、この血漿ポンプ７
１の回転数に基づいて血漿流路２の流量を検知する血液
量検知器８１が、上記ドレンポンプ７２には、このドレ
ンポンプ７２の回転数に基づいてドレン量を検知するド
レン量検知器８２が、それぞれ接続されている。Roughly speaking, the blood pump 4 includes a blood volume detector 5 that detects the flow rate of the blood circulation flow path 1 based on the rotation speed of the blood pump 4, and the plasma pump 71 includes a blood volume detector 5 that detects the flow rate of the blood circulation channel 1 based on the rotation speed of the blood pump 4.
The drain pump 72 includes a blood volume detector 81 that detects the flow rate of the plasma flow path 2 based on the rotation speed of the drain pump 72, and a drain amount detector 82 that detects the drain amount based on the rotation speed of the drain pump 72. are connected to each other.
４８はマイクロコンピュータからなる制御装置であり、
臨床時には−この制御装置４８により、上記各検知器５
．８１．８２からの流量検知信号と、各圧力センサ２３
．２４％２６．３７からの圧力検知信号とを見ながら、
血液循環流路１内と血漿流路２内の各流量、および血漿
分離器３と血漿成分分離器６内の膜圧が適正値となるよ
うに、上記各ポンプ４．７１７２の回転数を制御し、血
液の処理を行なう、、ここで、上記ドレンポンプ７２は
高分子ゑ成分の排出と補液の供給とを兼ねているが、゛
・・これとは異なり、高分子量成分の排出と補液の供給
とを別面のポンプで行なうようにしてもよい。ただし、
この実施例のように、兼用構成とすれば、特に制御しな
くても、高分子量成分の排出量と、補液の供給量とが常
ｇこ等１〜くなるので好都合である。48 is a control device consisting of a microcomputer;
During clinical use, this control device 48 controls each of the above-mentioned detectors 5.
．． Flow rate detection signals from 81 and 82 and each pressure sensor 23
．． 24%26.While looking at the pressure detection signal from 37,
The rotational speed of each pump 4.7172 is controlled so that the flow rates in the blood circulation channel 1 and the plasma channel 2 and the membrane pressures in the plasma separator 3 and plasma component separator 6 are at appropriate values. Here, the drain pump 72 serves both to discharge high molecular weight components and to supply replacement fluid, but unlike this, it discharges high molecular weight components and supplies replacement fluid. The supply may be performed by a pump on a separate surface. however,
If the dual-use structure is used as in this embodiment, it is advantageous because the discharge amount of the high molecular weight component and the supply amount of the replacement fluid will always be 1 to 1 g without any particular control.
上記血液循環流路ｌおよび種漿流路２は、第３図に示す
取付台５ｏの前面５０ａに取り付けられる。この前面５
０＆には第４図に示すように、塩化ビニール管で形成さ
れた血液循環流路１および血漿流路２が装着され、これ
ら血液循環流路１および血漿流路２の中途に、血漿分離
器３、血漿成分分離器６などが接続され、取付台５ｏの
上部には、血液ポンプ４、血漿ポンプ７１、ドレンポン
プ７２、および、操作の指示等を表示する画面５１が配
置されている。The blood circulation flow path 1 and the sesame flow path 2 are attached to the front surface 50a of the mounting base 5o shown in FIG. 3. This front 5
As shown in FIG. 4, the blood circulation channel 1 and plasma channel 2 formed of vinyl chloride pipes are attached to the 0&, and a plasma separator is installed in the middle of these blood circulation channel 1 and plasma channel 2. 3, a plasma component separator 6 and the like are connected, and a blood pump 4, a plasma pump 71, a drain pump 72, and a screen 51 for displaying operation instructions and the like are arranged on the top of the mount 5o.
のフローチャートにより説明する。This will be explained using a flowchart.
第５図において、血液処理が終了した時、血液循環流路
には血液、血漿循環流路には血漿が充満している。In FIG. 5, when blood processing is completed, the blood circulation channel is filled with blood and the plasma circulation channel is filled with plasma.
血液導出部Ｈ１は人体から取り外され、血液導入部Ｈｚ
４よ人体に接続されている６
また血液ポンプ４、血漿ポンプ７１、ドレンポンプ７２
は停止しており、バルブ１１．１７は開放されバルブ２
３２５．３８は閉止されている。The blood lead-out section H1 is removed from the human body, and the blood introduction section Hz
4 connected to the human body 6 Also blood pump 4, plasma pump 71, drain pump 72
is stopped, valves 11 and 17 are opened and valve 2
325.38 is closed.
以上が回収のスタート前の状態であり、第１２図のフロ
ーチャートのステップに１であり、第６図にこの状態を
示す。外部からの回収スタート信号を受けると、制御装
置４８が作動しバルブ１７．２０は開放し、バルブ１１
，２５．３８は閉止する。また血液ポンプ４が、例えば
４０ＷＬｌ／分の流量で回転を始め、血液導出部ａｔか
らは外部空気が吸入され、血液循環流路中の残血液は血
液導入部Ｈ２より人体に返却される。この状態は第１２
図のフローチャートのステップに２であり、第７図にこ
の状態を示す。このステップに２の状態が続くと、血漿
分離器３の血液がなくなり、次いで静脈チャンバー１８
の血液レベルが低下し、該チャンバーに設けられた検出
器１８Ｄ−Ａ！室空気検出し、次のステップＫｓに進む
。静脈チャンバー１８は、このステップに２の終期には
一空気が混入するので一短期間（例えば１秒以内）の空
気検出では次のステップに進まない様な安全策が鹿され
ている。The above is the state before the start of collection, step 1 in the flowchart of FIG. 12, and this state is shown in FIG. When receiving a collection start signal from the outside, the control device 48 is activated, valves 17 and 20 are opened, and valve 11 is opened.
, 25.38 are closed. Further, the blood pump 4 starts rotating at a flow rate of, for example, 40 WLl/min, external air is taken in from the blood outlet part at, and the remaining blood in the blood circulation channel is returned to the human body from the blood introduction part H2. This state is the 12th
Step 2 of the flowchart shown in the figure is step 2, and this state is shown in FIG. If condition 2 continues in this step, the blood in the plasma separator 3 runs out, and then the venous chamber 18
The blood level of the chamber decreases, and the detector 18D-A! Room air is detected and the process proceeds to the next step Ks. In the venous chamber 18, since some air will be mixed into this step at the end of step 2, a safety measure is taken to prevent the flow from proceeding to the next step if air is detected for a short period of time (for example, within 1 second).
血液導出部Ｈ１は外部開放せず、生理食塩水貯留器に接
続しても、Ｋ２のステップの処理時間が長くなるが、血
漿分離器３内の残血液がより完全に下流に追い出され、
血液回収効率が上昇し、生理食塩水が無くなると空気が
とり込まれるので、同様なフローで適応出来る。Even if the blood outlet H1 is not opened to the outside and is connected to a physiological saline reservoir, the processing time of the step K2 will be longer, but the remaining blood in the plasma separator 3 will be more completely expelled downstream.
Blood collection efficiency increases and air is taken in when saline runs out, so a similar flow can be applied.
に３ステツプではバルブ２５．２０が開放し、バルブ１
７，１１．３８が閉止して一面液ボンブ４を停止させ、
血漿ポンプ７１を、例えば４０ｒｎｌ／分の流量で回転
させて、血漿分離器３の残血漿をバルブ２５がら空気を
入れることにより血漿成分分離器６へ送出し始める。こ
の状態を第８図に示す。この時２次膜圧が静脈圧以上に
なるまで血漿成分分離器６の分離膜での血漿の逆流を防
止する為、バルブ１１は閉じておく。In step 3, valves 25 and 20 open and valve 1
7, 11.38 closes and stops the one-sided liquid bomb 4,
The plasma pump 71 is rotated at a flow rate of, for example, 40 rnl/min, and the remaining plasma in the plasma separator 3 is started to be delivered to the plasma component separator 6 by introducing air through the valve 25. This state is shown in FIG. At this time, the valve 11 is kept closed to prevent backflow of plasma across the separation membrane of the plasma component separator 6 until the secondary membrane pressure becomes equal to or higher than the venous pressure.
２次膜圧が静脈圧より大の条件が成立すると五４ステッ
プに進みバルブ１１を開き血漿ポンプ７１で血漿成分分
離器に送り込まれた血漿は、濾過され低分子型成分のみ
が血漿流路下流側回路を通り、静脈チャンバー１８を経
由して血液導入部Ｈ２より人体に戻される。この吠を歴
を第９図に示す。一方。When the condition that the secondary membrane pressure is greater than the venous pressure is established, the process proceeds to step 54, where the valve 11 is opened and the plasma sent to the plasma component separator by the plasma pump 71 is filtered and only low molecular components are passed downstream of the plasma flow path. The blood passes through the side circuit, passes through the venous chamber 18, and is returned to the human body from the blood introduction section H2. The history of this process is shown in Figure 9. on the other hand.
血漿分離器３の残血漿が無くなり、バルブ２５からは空
気が入ってきているのでしばらくすると、２成膜チャン
バー３２の血漿レベルは低下し、２成膜チャンバ１−３
２に設けられた検出器３９で空気が検出され、同時に血
漿ポンプ７１の累積流量が算出される。この流量が例え
ば１００ｍＪに達するまで血漿成分分離器６には血漿と
空気が送り込まれる。この１００ｍＪの値は血漿成分分
離器６の分離膜内容量に相当し、血漿成分分離器６では
空気は瀘過されないので、大破に空気を血漿成分分離器
６に送り込むことは、２次膜圧が上昇するのみで好まし
くない。血漿成分分離器６内の分離膜内が血漿から空気
に置換されると次のステップ。Since the remaining plasma in the plasma separator 3 is gone and air is coming in from the valve 25, the plasma level in the second film forming chamber 32 will decrease after a while, and the plasma level in the second film forming chamber 32 will decrease.
Air is detected by a detector 39 provided at 2, and at the same time the cumulative flow rate of the plasma pump 71 is calculated. Plasma and air are fed into the plasma component separator 6 until this flow rate reaches, for example, 100 mJ. This value of 100 mJ corresponds to the internal capacity of the separation membrane of the plasma component separator 6, and since air is not filtered in the plasma component separator 6, sending air into the plasma component separator 6 in a major manner is due to the secondary membrane pressure. This is not desirable as it only increases the Once the separation membrane in the plasma component separator 6 has been replaced with air from plasma, the next step begins.
Ｋｓに進む。Proceed to Ks.
Ｋｓのス娑ツブではドレンポンプ２５３例えば４０１／
分の流量で回転し残補液及び血漿成分分離器６で濾過さ
れた血漿が血漿流路の下流側を通り、静脈チャンバーを
経由して血液導入部出より人体に返却されるこの状態を
第１０図に示す。In the Ks slot, the drain pump 253, for example 401/
The remaining replacement fluid and plasma filtered by the plasma component separator 6 pass through the downstream side of the plasma flow path and are returned to the human body from the blood introduction part via the venous chamber. As shown in the figure.
また、この状態では血漿成分分離器６内の空気がドレン
ポンプより外部に排出されるので、分離器内の圧力が低
下して、補液が分離器内に逆流するのを防止するため、
２次膜圧が設定値例えば４００ ｍＨｇになる様、血漿
ポンプ７１を作動させる。In addition, in this state, the air inside the plasma component separator 6 is discharged to the outside from the drain pump, so the pressure inside the separator decreases and to prevent replacement fluid from flowing back into the separator.
The plasma pump 71 is operated so that the secondary membrane pressure reaches a set value, for example, 400 mHg.
補液がなくなると、空気が入り、血漿成分分離器６から
バルブ１１を通り、静脈圧チャンバー１８を経由して検
出″ａ１９を通過する。検知器１９が空気を検出すると
バルブ２０を閉じて、ドレンポンプを一旦停止し、次に
第１１図に示すに６ステツプに移る。When the replacement fluid runs out, air enters, passes through the valve 11 from the plasma component separator 6, passes through the venous pressure chamber 18, and passes through the detection "a19". When the detector 19 detects air, the valve 20 is closed and the drain is drained. The pump is temporarily stopped and then the process moves to step 6 as shown in FIG.
この状態では血漿は血液循環流路１の検出器１９と血液
導出部ｔｌｚの間に残っており、Ｋ７、Ｋｓのステップ
に示す様、スタートスイッチで血漿を血液導入部■２の
近くまで追い込んでストップスイッチで止めることによ
り一血漿も完全に回収出来る。In this state, the plasma remains between the detector 19 of the blood circulation channel 1 and the blood outlet section tlz, and as shown in steps K7 and Ks, the plasma is driven close to the blood introduction section 2 using the start switch. By turning off the stop switch, even one plasma can be completely collected.
以上説明したように、この発明によれば、臨床処理終了
後、血液導出部を人体から取り外し回収スタートスイッ
チを押すだけで、血液循環流路中の残血液と［ｆ［Ｌ漿
流路中の残血漿を完全に回収できる。As explained above, according to the present invention, after the clinical treatment is completed, by simply removing the blood outlet part from the human body and pressing the recovery start switch, the remaining blood in the blood circulation channel and [f[L in the serum channel] can be removed. Residual plasma can be completely recovered.
上記操作は全て自動で行われるため、操作が簡単で習熟
したテクニックを必要とせず、きわめて安全に回収が出
来る。All of the above operations are performed automatically, so they are easy to operate, do not require experienced techniques, and can be collected extremely safely.
第１図はこの発明の構成を示す回路図、第２図はこの発
明に係る二！濾過型血液処理装置の血液処理時の状態を
示す回路図、第３図はこの発明の装置が取り付けられる
取付台を示す側面図、ｗｉ４施例の制御方法を示すフロ
ーチャートである。
１・・・血液循環流路、２・・・血漿流路、３・・・血
漿分離器、４・・・血液ポンプ、１８Ｄ・・・第１の検
知器、６・・・血漿成分分離器、８・・・ｆＲ５の検知
器、９・・・補液供給源、１１・・・第３のバルブ−１
３・・・血液回収手段、１４・・・補液回収手段、１５
・・・血漿回収手段、１６・・・回収終了手段、１７・
・・第２のバルブ、１９・・・第１の検知器、２０・・
・第１のバルブ、２５・・・第４のバルブ、３７・・・
第３の検知器、３９・・・ｆ１３４４の検知器FIG. 1 is a circuit diagram showing the configuration of this invention, and FIG. 2 is a circuit diagram showing the configuration of this invention. FIG. 3 is a circuit diagram showing the state of the filtration type blood processing device during blood processing; FIG. 3 is a side view showing a mounting base to which the device of the present invention is attached; and a flowchart showing a control method of the wi4 embodiment. DESCRIPTION OF SYMBOLS 1... Blood circulation channel, 2... Plasma channel, 3... Plasma separator, 4... Blood pump, 18D... First detector, 6... Plasma component separator , 8... fR5 detector, 9... replacement fluid supply source, 11... third valve-1
3... Blood collection means, 14... Replacement fluid collection means, 15
...Plasma collection means, 16... Collection termination means, 17.
...Second valve, 19...First detector, 20...
・First valve, 25...Fourth valve, 37...
Third detector, 39...f1344 detector
Claims (1)
分と血漿成分とに分離し、血球成分を人体に返還する血
液循環流路１と、 該血漿分離器３で分離された血漿成分を血漿ポンプ７１
で血漿成分分離器６に供給して、高分子量成分と低分子
量成分とに分離し、該分離された低分子量成分に、廃棄
される高分子量成分と等量の補液を補液ポンプ７２で加
えて混合した後、血漿分離器よりも下流の血液循環流路
１を経て人体へ返還する血漿流路２と、 該血漿分離器３の下流の血液循環流路１内の流体を識別
する、互いに離間して設けた第１および第２の検知器１
８Ｄ、１９と、 該血漿ポンプ７１の下流の血漿流路２内の流体を識別す
る第４の検知器３９と、 該第２の検知器１９の下流の血液循環流路１を開閉する
第１のバルブ２０と、 該血漿分離器３の下流の血液循環流路１を開閉する第２
のバルブ１７と、 該血漿流路２と該血漿分離器３よりも下流の血液循環流
路１との連通および遮断を行う第３のバルブ１１と、 該血漿分離器３のろ液室の上部に設けた空気導入口を開
閉する第４のバルブ２５と、 外部からのスタート信号を受けて、血液ポンプ４を駆動
し、第３のバルブ１１を閉止し、第１のバルブ２０と第
２のバルブ１７を開放する血液回収手段１３と 該第１の検知器１８Ｄからの気体検知信号を受けて、第
２のバルブ１７を閉止し、第３のバルブ１１と第４のバ
ルブ２５を開放して、血液ポンプ４を停止し、血漿ポン
プ７１を駆動する血漿回収手段１５と、 該第４の検知器３９からの気体検知信号を受けて補液ポ
ンプ７２を駆動する補液回収手段１４と、該第２の検知
器１９からの気体検知信号を受けて、第１のバルブ２０
を閉止し、血漿ポンプ７１の駆動を停止する回収終了手
段１５ を備えたことを特徴とする二重ろ過型血液処理装置。[Scope of Claims] A blood circulation channel 1 that separates blood supplied to a plasma separator 3 by a blood pump 4 into blood cell components and plasma components, and returns the blood cell components to the human body; The separated plasma components are transferred to the plasma pump 71.
is supplied to the plasma component separator 6 to separate it into a high molecular weight component and a low molecular weight component, and a replacement fluid in an amount equal to the high molecular weight component to be discarded is added to the separated low molecular weight component using a replacement fluid pump 72. After mixing, the plasma flow path 2 which returns to the human body via the blood circulation flow path 1 downstream of the plasma separator 3 and the fluid in the blood circulation flow path 1 downstream of the plasma separator 3 are identified and separated from each other. The first and second detectors 1 provided as
8D, 19; a fourth detector 39 for identifying fluid in the plasma flow path 2 downstream of the plasma pump 71; and a first detector 39 for opening and closing the blood circulation flow path 1 downstream of the second detector 19. a second valve 20 for opening and closing the blood circulation channel 1 downstream of the plasma separator 3;
a third valve 11 that communicates with and shuts off the plasma flow path 2 and the blood circulation flow path 1 downstream of the plasma separator 3; and an upper part of the filtrate chamber of the plasma separator 3. A fourth valve 25 that opens and closes an air inlet provided in the In response to the blood collection means 13 opening the valve 17 and the gas detection signal from the first detector 18D, the second valve 17 is closed and the third valve 11 and the fourth valve 25 are opened. , a plasma collection means 15 which stops the blood pump 4 and drives the plasma pump 71; a replacement fluid collection means 14 which receives a gas detection signal from the fourth detector 39 and drives the replacement fluid pump 72; In response to the gas detection signal from the detector 19, the first valve 20
A double filtration type blood processing device characterized by comprising a collection termination means 15 for closing the plasma pump 71 and stopping the drive of the plasma pump 71.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60284797A JPS62142567A (en) | 1985-12-17 | 1985-12-17 | Double filtering type blood treatment apparatus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP60284797A JPS62142567A (en) | 1985-12-17 | 1985-12-17 | Double filtering type blood treatment apparatus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS62142567A true JPS62142567A (en) | 1987-06-25 |
| JPH0117704B2 JPH0117704B2 (en) | 1989-03-31 |
Family
ID=17683139
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP60284797A Granted JPS62142567A (en) | 1985-12-17 | 1985-12-17 | Double filtering type blood treatment apparatus |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS62142567A (en) |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS645563A (en) * | 1987-06-30 | 1989-01-10 | Terumo Corp | Apparatus for removing unnecessary substance in blood |
| JPS649652U (en) * | 1987-07-03 | 1989-01-19 | ||
| JP2013188427A (en) * | 2012-03-15 | 2013-09-26 | Asahi Kasei Medical Co Ltd | Ascites processing device and ascites processing method |
| JP2013208162A (en) * | 2012-03-30 | 2013-10-10 | Nikkiso Co Ltd | Blood purifier |
| JP2016047472A (en) * | 2016-01-08 | 2016-04-07 | 日機装株式会社 | Blood purifier |
| JP2016047471A (en) * | 2016-01-08 | 2016-04-07 | 日機装株式会社 | Blood purifier |
| JP2016083420A (en) * | 2016-01-08 | 2016-05-19 | 日機装株式会社 | Blood purifier |
| EP3932448A4 (en) * | 2019-04-01 | 2022-11-30 | Nikkiso Co., Ltd. | Blood purification device |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5385917B2 (en) * | 2008-11-19 | 2014-01-08 | 旭化成メディカル株式会社 | Plasma purification apparatus and blood purification apparatus control method |
-
1985
- 1985-12-17 JP JP60284797A patent/JPS62142567A/en active Granted
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS645563A (en) * | 1987-06-30 | 1989-01-10 | Terumo Corp | Apparatus for removing unnecessary substance in blood |
| JPH0580909B2 (en) * | 1987-06-30 | 1993-11-10 | Terumo Corp | |
| JPS649652U (en) * | 1987-07-03 | 1989-01-19 | ||
| JP2013188427A (en) * | 2012-03-15 | 2013-09-26 | Asahi Kasei Medical Co Ltd | Ascites processing device and ascites processing method |
| JP2013208162A (en) * | 2012-03-30 | 2013-10-10 | Nikkiso Co Ltd | Blood purifier |
| JP2016047472A (en) * | 2016-01-08 | 2016-04-07 | 日機装株式会社 | Blood purifier |
| JP2016047471A (en) * | 2016-01-08 | 2016-04-07 | 日機装株式会社 | Blood purifier |
| JP2016083420A (en) * | 2016-01-08 | 2016-05-19 | 日機装株式会社 | Blood purifier |
| EP3932448A4 (en) * | 2019-04-01 | 2022-11-30 | Nikkiso Co., Ltd. | Blood purification device |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH0117704B2 (en) | 1989-03-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6855119B2 (en) | Apparatus for sequestering platelet rich plasma | |
| US5876611A (en) | Intraoperative blood salvaging system and method | |
| US4828543A (en) | Extracorporeal circulation apparatus | |
| US4747952A (en) | Method and apparatus for plasma treatment | |
| EP0228160B1 (en) | Apparatus for the filtration of plasma from blood | |
| JPS62142567A (en) | Double filtering type blood treatment apparatus | |
| WO1998029149A1 (en) | Intraoperative blood salvaging system and method | |
| JPS62254765A (en) | Blood treatment apparatus | |
| JPS63315061A (en) | Automatic washing apparatus of blood treatment device | |
| JPH0446756Y2 (en) | ||
| JPH0244759Y2 (en) | ||
| JPS62137060A (en) | Double filtering type blood treatment apparatus | |
| JPS62120853A (en) | Serum separating apparatus | |
| JPH059008Y2 (en) | ||
| JPH0651058B2 (en) | Plasma separator | |
| JPH0244760Y2 (en) | ||
| JPS63292964A (en) | Plasma treatment apparatus | |
| JPH0225407Y2 (en) | ||
| JPS62137061A (en) | Double filtering type blood treatment apparatus | |
| JPH0653162B2 (en) | Blood processing apparatus provided with blood collecting means | |
| JPH0244761Y2 (en) | ||
| JPS6219177A (en) | Blood treating apparatus | |
| JPH0228982B2 (en) | ||
| JPH0550302B2 (en) | ||
| JPS63279853A (en) | Plasma treatment apparatus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| EXPY | Cancellation because of completion of term |